211 related articles for article (PubMed ID: 30082157)
21. Epithelial-mesenchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma.
Kim A; Bae YK; Gu MJ; Kim JY; Jang KY; Bae HI; Lee HJ; Hong SM
Pathology; 2013 Oct; 45(6):567-73. PubMed ID: 24018801
[TBL] [Abstract][Full Text] [Related]
22. Sarcomatoid carcinoma represents a complete phenotype with various pathways of epithelial mesenchymal transition.
Sung CO; Choi H; Lee KW; Kim SH
J Clin Pathol; 2013 Jul; 66(7):601-6. PubMed ID: 23533257
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma.
Shim HS; Yoon BS; Cho NH
Hum Pathol; 2009 May; 40(5):693-8. PubMed ID: 19157508
[TBL] [Abstract][Full Text] [Related]
24. Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.
Cheng S; Guo J; Yang Q; Yang X
Med Oncol; 2015 Mar; 32(3):47. PubMed ID: 25636509
[TBL] [Abstract][Full Text] [Related]
25. α-Smooth muscle actin-positive myofibroblasts, in association with epithelial-mesenchymal transition and lymphogenesis, is a critical prognostic parameter in patients with oral tongue squamous cell carcinoma.
Ding L; Zhang Z; Shang D; Cheng J; Yuan H; Wu Y; Song X; Jiang H
J Oral Pathol Med; 2014 May; 43(5):335-43. PubMed ID: 24313357
[TBL] [Abstract][Full Text] [Related]
26. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.
Ren C; Du J; Xi C; Yu Y; Hu A; Zhan J; Guo H; Fang W; Liu C; Zhang H
Biochem Biophys Res Commun; 2014 Mar; 446(1):187-94. PubMed ID: 24583125
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
28. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.
Hannibal CG; Vang R; Junge J; Kjaerbye-Thygesen A; Kurman RJ; Kjaer SK
Gynecol Oncol; 2012 Jun; 125(3):655-60. PubMed ID: 22370600
[TBL] [Abstract][Full Text] [Related]
29. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.
Auer K; Bachmayr-Heyda A; Aust S; Sukhbaatar N; Reiner AT; Grimm C; Horvat R; Zeillinger R; Pils D
Oncotarget; 2015 Jul; 6(19):17261-75. PubMed ID: 25991672
[TBL] [Abstract][Full Text] [Related]
30. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
[TBL] [Abstract][Full Text] [Related]
31. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
Chai Y; Wu W; Zhou C; Zhou J
Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
[TBL] [Abstract][Full Text] [Related]
32. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.
Stoyianni A; Goussia A; Pentheroudakis G; Siozopoulou V; Ioachim E; Krikelis D; Golfinopoulos V; Cervantes A; Bobos M; Fotsis T; Bellou S; Fountzilas G; Malamou-Mitsi V; Pavlidis N
Anticancer Res; 2012 Apr; 32(4):1273-81. PubMed ID: 22493359
[TBL] [Abstract][Full Text] [Related]
34. p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells.
Pon YL; Zhou HY; Cheung AN; Ngan HY; Wong AS
Cancer Res; 2008 Aug; 68(16):6524-32. PubMed ID: 18701475
[TBL] [Abstract][Full Text] [Related]
35. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
36. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
[TBL] [Abstract][Full Text] [Related]
37. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
Chen X; Zhang J; Zhang Z; Li H; Cheng W; Liu J
Hum Pathol; 2013 Nov; 44(11):2373-84. PubMed ID: 23850493
[TBL] [Abstract][Full Text] [Related]
38. IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer.
Su P; Hu J; Zhang H; Li W; Jia M; Zhang X; Wu X; Cheng H; Xiang L; Zhou G
Int J Clin Exp Pathol; 2014; 7(6):3008-17. PubMed ID: 25031719
[TBL] [Abstract][Full Text] [Related]
39. [Serous ovarian tumors].
Diebold J
Pathologe; 2014 Jul; 35(4):314-21. PubMed ID: 24916775
[TBL] [Abstract][Full Text] [Related]
40. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis.
Tsofack SP; Meunier L; Sanchez L; Madore J; Provencher D; Mes-Masson AM; Lebel M
BMC Cancer; 2013 Jun; 13():303. PubMed ID: 23800275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
